146 related articles for article (PubMed ID: 35305420)
1. Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma.
Chen S; Li X; Wang H; Chen G; Zhou Y
Biochem Biophys Res Commun; 2022 May; 604():158-164. PubMed ID: 35305420
[TBL] [Abstract][Full Text] [Related]
2. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
Hamerlik P; Lathia JD; Rasmussen R; Wu Q; Bartkova J; Lee M; Moudry P; Bartek J; Fischer W; Lukas J; Rich JN; Bartek J
J Exp Med; 2012 Mar; 209(3):507-20. PubMed ID: 22393126
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
4. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
7. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
8. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
9. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
10. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
11. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
12. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
13. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
14. Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis.
Jiang X; Huang Y; Wang X; Liang Q; Li Y; Li F; Fu X; Huang C; Liu H
Biomed Pharmacother; 2017 Jul; 91():1065-1074. PubMed ID: 28525947
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
16. Pseudogene MAPK6P4-encoded functional peptide promotes glioblastoma vasculogenic mimicry development.
Zhang M; Zhao Y; Liu X; Ruan X; Wang P; Liu L; Wang D; Dong W; Yang C; Xue Y
Commun Biol; 2023 Oct; 6(1):1059. PubMed ID: 37853052
[TBL] [Abstract][Full Text] [Related]
17. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
19. ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.
Chen L; Xie X; Wang T; Xu L; Zhai Z; Wu H; Deng L; Lu Q; Chen Z; Yang X; Lu H; Chen YG; Luo S
Neuro Oncol; 2023 May; 25(5):871-885. PubMed ID: 36322624
[TBL] [Abstract][Full Text] [Related]
20. Exosome-transmitted ANGPTL1 suppresses angiogenesis in glioblastoma by inhibiting the VEGFA/VEGFR2/Akt/eNOS pathway.
Wang D; Li H; Zeng T; Chen Q; Huang W; Huang Y; Liao Y; Jiang Q
J Neuroimmunol; 2024 Feb; 387():578266. PubMed ID: 38150891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]